Miglustat in Niemann-Pick type C (NPC) disease: Results of 12-months-treatment
Miglustat in Niemann-Pick type C (NPC) disease: Results of 12-months ...
D Vecchio (13425981) +3 more
core
Miglustat in Neuronopathic Lysosomal Storage Disorders: Biological Rationale, Clinical Evidence, and Limits of Repurposing. [PDF]
Lipiński P, Węgrzyn G.
europepmc +1 more source
Aspiration and silent aspiration in Niemann-Pick disease type C1: longitudinal findings from the NIH natural history study. [PDF]
Solomon BI +8 more
europepmc +1 more source
Defining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement. [PDF]
Schoser B.
europepmc +1 more source
Correction: Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N‑of‑1 Trial with 21 months Clinical Observation. [PDF]
Cook A +14 more
europepmc +1 more source
Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy. [PDF]
Mengel E +6 more
europepmc +1 more source
Assessing Surface Binding Events on Golgi Microsomes Isolated from Cancer Cells by Capillary Electrophoresis. [PDF]
Davoine C +3 more
europepmc +1 more source
A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa. [PDF]
Dymond A +9 more
europepmc +1 more source
Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data. [PDF]
Fu S +8 more
europepmc +1 more source
From Neonatal Cholestasis to Progressive Neurological Impairment: A Case of Niemann-Pick Disease Type C. [PDF]
Carvalho de Sousa L +2 more
europepmc +1 more source

